BS_MV6ASWV9
ATRT
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- ATRT
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- ATRT
- overall_survival_months
- 19.053876478318003
- age_years
- 4.126
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.702
- MYC_TARGETS_V1+0.650
- MYC_TARGETS_V2+0.612
- G2M_CHECKPOINT+0.575
- MTORC1_SIGNALING+0.532
- UNFOLDED_PROTEIN_RESPONSE+0.422
- DNA_REPAIR+0.370
- OXIDATIVE_PHOSPHORYLATION+0.360
- PROTEIN_SECRETION+0.355
- SPERMATOGENESIS+0.342
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.543
- IL6_JAK_STAT3_SIGNALING-0.472
- INTERFERON_GAMMA_RESPONSE-0.463
- ALLOGRAFT_REJECTION-0.426
- INFLAMMATORY_RESPONSE-0.423
- COMPLEMENT-0.370
- KRAS_SIGNALING_UP-0.336
- TGF_BETA_SIGNALING-0.330
- TNFA_SIGNALING_VIA_NFKB-0.330
- MYOGENESIS-0.318
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2956 | Med | Medulloblastoma | 0.948 |
| 2 | SRR1313140 | — | E | 0.934 |
| 3 | MNG1063 | — | — | 0.920 |
| 4 | MBCProject_4634_T1_RNA | — | E | 0.919 |
| 5 | SRR8613799 | — | E | 0.918 |
| 6 | BS_052PZFMK | high-grade glioma | — | 0.917 |
| 7 | AUR-AFR3-TTM1-A-1-1-R-A743-41 | — | C | 0.916 |
| 8 | MNG534 | — | — | 0.914 |
| 9 | MNG1195 | — | — | 0.913 |
| 10 | SRR4296106 | — | cohortSQ1 | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.702 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.650 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.612 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.575 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.532 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.422 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.355 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.342 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.296 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.279 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.232 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.192 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.123 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.065 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.054 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.028 | Cobimetinib | — uncovered |